The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: Results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study

British Journal of Cancer

Volumn 97, Issue 3, 2007, Pages 302-307

  Mauer, M ^a   Stupp, R ^b   Taphoorn, M J B ^c   Coens, C ^a   Osoba, D ^d   Marosi, C ^e   Wong, R ^f   De Witte, O ^g   Cairncross, J G ^h   Efficace, F ^a   Mirimanoff, R O ^b   Forsyth, P ^h   Van Den Bent, M J ⁱ   Weller, M ^j   Bottomley, A ^a  

^a EORTC DATA CENTER   (Belgium)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c MEDICAL CENTER HAAGLANDEN   (Netherlands)

^d QOL Consulting   (Canada)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f JURAVINSKI CANCER CENTRE   (Canada)

^g ERASME HOSPITAL   (Belgium)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF TÜBINGEN   (Germany)

more..

Author keywords

Glioblastoma; HRQOL scores; Prognostic factors

Indexed keywords

TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HAZARD ASSESSMENT; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SOCIAL STATUS; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS;

BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 34547574155     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603876     Document Type: Article

References (34)

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376
2. Blazeby JM, Brookes ST, Alderson D (2001) The prognostic value of quality of life scores during treatment for oesophageal cancer. Gut 49: 227-230
3. Bottomley A, Flechtner H, Efficace F, Vanvoorden V, Coens C, Therasse P, Velikova G, Blazeby J, Greimel E (2005) Health related quality of life outcomes in cancer clinical trials. Eur J Cancer 41: 1697-1709
4. Bottomley A, Vanvoorden V, Flechtner H, Therasse P (2003) The challenge and achievements of implementation of quality of life research in cancer clinical trials. Eur J Cancer 39: 275-285
5. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11(3): 570-579
6. Cheng JD, Hitt J, Koczwara B, Schulman KA, Burnett CB, Gaskin DJ, Rowland JH, Meropol NJ (2000) Impact of quality of life on patient expectations regarding phase I clinical trials. J Clin Oncol 18(2): 421-428
7. Coates AS, Hurny C, Peterson HF, Bernhard J, Castiglione-Gertsch M, Gelber RD, Goldhirsch A (2000) Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group. J Clin Oncol 18(22): 3768-3774
8. Collett D (1994) Modelling Survival Data in Medical Research. Chapman & Hall: London
9. Cox DR (1972) Regression models and life tables. J Royal Stat Soc 34: 187-220
10. Cull A, Sprangers M, Bjordal K, Aaronson N (2002) EORTC Quality of Life Group Translation Procedure. EORTC Publications: Brussels, ISBN: 2-930064-28-5
11. de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA (2001) Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. Eur J Cancer 37: 332-339
12. Detmar SB, Muller MJ, Schornagel JH, Wever LD, Aaronson NK (2002) Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA 288(23): 3027-3034
13. Efficace F, Biganzoli L, Piccart M, Coens C, Van Steen K, Cufer T, Coleman RE, Calvert HA, Gamucci T, Twelves C, Fargeot P, Bottomley A (2004a) Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 40(7): 1021-1030
14. Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, Schramel F, Smit HJ, Gaafar R, Biesma B, Manegold C, Coens C, Giaccone G, Van Meerbeeck J (2006) Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 17(11): 1698-1704
15. Efficace F, Therasse P, Piccart MJ, Coens C, van Steen K, Welnicka-Jaskiewicz M, Cufer T, Dyczka J, Lichinitser M, Shepherd L, de Haes H, Sprangers MA, Bottomley A (2004b) Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study. J Clin Oncol 22(16): 3381-3388
16. Fang FM, Tsai WL, Chiu HC, Kuo WR, Hsiung CY (2004) Quality of life as a survival predictor for esophageal squamous cell carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 58: 1394-1404
17. Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 Scoring Manual. EORTC Publications: Brussels, ISBN: 2-930064-22-6
18. Gorlia T, van den Bent MJ, Hegi M. Nomograms for predicting survival of patients with newly diagnosed glioblastoma multiforme: a prognostic factor analysis of EORTC/NCIC trial 26981-22981/CE. Clin Oncol (in press)
19. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10): 997-1003
20. Herndon JE, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J (1999) Is quality of life predictive of the survival of patients with advanced non-small cell lung carcinoma? Cancer 5 85(2): 333-340
21. Klein M, Postma TJ, Taphoorn MJ, Aaronson NK, Vandertop WP, Muller M, van der Ploeg HM, Heimans JJ (2003) The prognostic value of cognitive functioning in the survival of patients with high-grade glioma. Neurology 61(12): 1796-1798
22. Kramer JA, Curran D, Piccart M, de Haes JC, Bruning P, Klijn J, Van Hoorebeeck I, Paridaens R (2000) Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36: 1498-1506
23. Langendijk H, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Wouters M (2000) The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol 55: 19-25
24. Luoma ML, Hakamies-Blomqvist L, Sjöström J, Pluzanska A, Ottoson S, Mouridsen H, Bengtsson NO, Bergh J, Malmstrom P, Valvere V, Tennvall L, Blomqvist C (2003) Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer. Eur J Cancer 39(10): 1370-1376
25. Meyers CA, Hess KR, Yung WK, Levin VA (2000) Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18(3): 646-650
26. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24(16): 2563-2569
27. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR (2001) Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer 31(2-3): 233-240
28. Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, Brada M, Newlands E (1996) The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 5(1): 139-150
29. Sauerbrei W, Schumacher M (1992) A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 11: 2093-2109
30. Sehlen S, Lenk M, Hollenhorst H, Schymura B, Aydemir U, Herschbach P, Duhmke E (2003) Quality of life (QoL) as predictive mediator variable for survival in patients with intracerebral neoplasma during radiotherapy. Onkologie 26(1): 38-43
31. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10): 987-996
32. Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, Mason W, Mirimanoff RO, Baumert BG, Eisenhauer E, Forsyth P, Bottomley A (2005) Health-related quality of life in patients with glioblastoma: a randomized controlled trial. Lancet Oncol 6(12): 937-944
33. Van Steen K, Curran D, Kramer J, Molenberghs G, Van Vreckem A, Bottomley A, Sylvester R (2002) Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection. Stat Med 21(24): 3865-3884
34. Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, Selby PJ (2004) Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol 22(4): 714-724